Dalal Street Investment Journal Digital
May 3, 2025
Caribou Biosciences CEO Rachel Haurwitz, Ph.D., has nothing but praise for the autologous CAR-T cell therapies that have provided another option for lymphoma patients. It’s just that her CRISPR gene editing company would like to do it better with an off-the-shelf approach.
In a fresh cut of data from the dose-escalation portion of the biotech’s phase 1 ANTLER trial, allogeneic cell therapy CB-010 has shown deepening overall response rates, complete response rates and a continued complete response rate at the six-month mark post-treatment.
But a familiar problem appears in this data that has led to questions in previous readouts: durability. Patients received the same lympho-deletion conditioning therapy and one of three doses—either 40 million CAR-T cells, 80 million or 120 million.
Nine out of 16 patients experienced progressive disease, with the therapy posting a 94% ORR and a 69% CR, as well as a 44% CR rate at six months.
Caribou's shares dropped nearly 11% to $7.71 in after-market trading Thursday after the results were released, compared to $8.14 at close.
“I wish CAR-T was the magic bullet that led to disease remission for every patient for all time. Unfortunately, that is not the case,” Haurwitz said. She says the 44% rate at six months is an important benchmark of durability.
Related Posts
McDonalds
May 3, 2025
ABC Job Placement
May 3, 2025
Gujarat Conex
May 3, 2025
emiway bantai
May 3, 2025
Rasthal: Best snacks for kids lunchbox
May 3, 2025
Hitesh Pandya
May 3, 2025
Clean Ganga Mission (Namami Gange)
May 3, 2025